The 2016 ATS/CDC/IDSA tuberculosis (TB) treatment guidelines recommend daily TB treatment in both the intensive and continuation phases of treatment in HIV-infected persons to decrease the risk of relapse and acquired drug resistance. However, guidelines vary across regions and countries, and treatment is given 7, 5, 3, or 2 days/week. The effect of TB treatment intermittency in the continuation phase on mortality in HIV-infected persons is unknown; we are unaware of clinical trials addressing this issue.
An observational cohort study was performed of HIV-infected adults treated for TB with standard therapy (2-month initiation phase of daily isoniazid, rifampin, pyrazinamide ± ethambutol) and continuation phase of isoniazid and rifampin, administered concomitantly with antiretroviral therapy (ART) at participating Caribbean, Central and South America network for HIV epidemiology (CCASAnet) sites (Argentina, Brazil, Chile, Honduras, Mexico, Peru) between 2000-2013. Known CD4 at TB diagnosis and timing of ART and TB treatment were also inclusion criteria. Kaplan-Meier and Cox proportional hazards methods compared time to death between groups.
527 TB/HIV patients met inclusion criteria: 245 (46%) received TB treatment 7 days/week, 16 (3%) 5 days/week, 84 (16%) 3 days/week, and 182 (35%) 2 days/week in the continuation phase. Intermittency varied by site: 182 / 261 (70%) of patients receiving continuation phase treatment 5-7 days/week were from Brazil, and 209 / 266 (79%) receiving treatment 2-3 days/week were from Peru. The crude risk of death was lower among those receiving treatment 5-7 vs. 2-3 days/week (P<0.001) (Figure). After adjusting for age, sex, CD4, ART use at TB diagnosis, and site of TB disease (pulmonary vs. extrapulmonary), mortality risk tended to be lower for those treated 5-7 days/week (HR 0.62, 95%CI 0.38, 1.04; P=0.07). However, after also stratifying by clinic site, there was no protective effect (HR 1.60, 95%CI 0.64-4.00; P=0.31).
TB treatment 5-7 days/week appeared to be associated with decreased risk of death compared to TB treatment 2-3 days/week in the continuation phase. However, although variation in TB treatment intermittency by country permitted this comparison, the results could have been driven by other differences between clinic sites. Prospective randomized trials are needed to more clearly assess optimum TB treatment frequency during the continuation phase in TB/HIV populations.